CelLBxHealth PLC
DWV
Company Profile
Business description
CelLBxHealth PLC is engaged in the development and commercialisation of the Parsortix platform, with deployment in liquid biopsy - non-invasive cancer diagnostics. It operates in single segment of commercialisation of its Parsortix cell separation platform. It generates revenue from contracts with customers in the research-use market, with customers located across multiple geographic regions. Geographically it operates in UK, Europe, North America, and Rest of World with majority of revenue deriving from Europe and North America.
Contact
10 Nugent Road
The Surrey Research Park
Surrey
GuildfordGU2 7AF
GBRT: +44 1483343434
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
114
Stocks News & Analysis
stocks
ASX biotech expands diagnostics portfolio after FDA approval
FDA nod adds another growth driver for ASX share.
stocks
Is it time to bail on Australian stocks?
Is your home bias costing your portfolio better returns?
stocks
ASX share undervalued despite margin woes
Short term margin pressure yet shares remain undervalued on improved outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,874.50 | 25.20 | 0.28% |
| CAC 40 | 8,140.59 | 50.31 | 0.62% |
| DAX 40 | 25,537.75 | 135.47 | 0.53% |
| Dow JONES (US) | 51,567.15 | 525.96 | -1.01% |
| FTSE 100 | 10,688.47 | 30.34 | 0.28% |
| HKSE | 24,713.78 | 46.54 | 0.19% |
| NASDAQ | 25,970.28 | 11.29 | -0.04% |
| Nikkei 225 | 63,923.00 | 438.90 | 0.69% |
| NZX 50 Index | 13,622.72 | 138.50 | 1.03% |
| S&P 500 | 7,554.18 | 31.55 | -0.42% |
| S&P/ASX 200 | 8,696.50 | 24.00 | 0.28% |
| SSE Composite Index | 3,891.60 | 27.32 | 0.71% |